Skip to main content
International
Ask us anything:
  • About
        • About We challenge convention so healthy can be possible
        • Our Story
          • Amneal at-a-glance
          • Our Founders
          • Our Milestones
        • Our Purpose & Commitments
        • Our Culture
          • Rise, Lead, Succeed
        • Our Leadership
          • Executive Leadership
          • Board of Directors
        • Our Locations
        • Responsibility
          • The Amneal Patient Assistance Programs
          • Product Donations
          • National & Local Philanthropy
          • Compliance and Ethics
        • Patient Community Connections
          • Our Commitment to Parkinson's
        • Awards & Recognition
  • Products
        • Products We create essential medicines
        • Our Portfolio
          • Biosciences
          • Generic Products
          • Specialty Products
          • Product Catalog
        • Quality
        • Drug Safety
          • Adverse Event Reporting
          • Medical Inquiries
          • Product Complaints
        • Operations
  • Research & Development
        • Research & Development We invest significantly in new product development
        • Generics R&D
        • Specialty R&D
          • Drug Delivery Technologies
        • Product Partnering
  • Investors
        • Investors Become an Informed Investor
  • News
  • Careers
        • Careers Help make healthy possible
        • Total Rewards
        • Search Our Career Opportunities
  • Contact
  • Customer Login
Amneal Pharmaceuticals
  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds

Home Home  >  News  >  Press Releases

  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds
Normal
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Dec 13, 2012
Impax Laboratories Names Bryan M. Reasons as Chief Financial Officer
Nov 21, 2012
Impax Laboratories Enters Into Development, Manufacturing and Commercialization Agreement with Perrigo
Nov 20, 2012
Impax Laboratories to Present at the Piper Jaffray 24th Annual Healthcare Conference
Nov 16, 2012
Impax Laboratories and ThoRx Laboratories Confirm Patent Challenge Relating to Generic OPANA® ER 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, and 40 mg
Nov 08, 2012
Impax Laboratories to Present at the Credit Suisse 2012 Healthcare Conference
Oct 30, 2012
Impax Laboratories Reports Third Quarter 2012 Results
Oct 12, 2012
Impax Pharmaceuticals Announces Extension of RytaryTM FDA Review Date to January 21, 2013
Oct 10, 2012
Impax Laboratories Announces Time Change for Third Quarter 2012 Earnings Conference Call on October 30
Oct 09, 2012
Impax Laboratories Schedules Conference Call and Webcast for Third Quarter 2012 Financial Results
Sep 17, 2012
Impax Laboratories to Present at the UBS Global Life Sciences Conference
Sep 14, 2012
Impax Laboratories Announces Settlement of Litigation Relating to CONCERTA®
Sep 04, 2012
Impax Laboratories Announces Settlement of Litigation Relating to RENVELA® and RENAGEL®
Jul 31, 2012
Impax Laboratories Reports Second Quarter 2012 Adjusted EPS Increased to $0.60; GAAP EPS Increased to $0.27
Jul 10, 2012
Impax Laboratories Schedules Conference Call and Webcast for Second Quarter 2012 Financial Results
Jun 29, 2012
Impax Laboratories Announces Resignation of Arthur A. Koch
Jun 26, 2012
Impax Laboratories Enters Into Development, Supply and Distribution Agreement with TOLMAR, Inc.
Jun 14, 2012
Impax Laboratories to Present at the Wells Fargo Securities Healthcare Conference
Jun 06, 2012
Amneal Upgrades Generic Metformin Family by Listening to Customers
PDF format download (opens in new window)
Jun 04, 2012
Impax Laboratories to Present at the Goldman Sachs Annual Global Healthcare Conference
May 22, 2012
Impax Laboratories Announces Voting Results from 2012 Annual Meeting of Stockholders
May 15, 2012
Amneal Pharmaceuticals Bucks Trend and Adds U.S. Manufacturing Jobs with Major Expansion
PDF format download (opens in new window)
May 10, 2012
Impax Laboratories to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
May 01, 2012
Impax Laboratories Reports Adjusted First Quarter 2012 EPS of $0.52; GAAP EPS of $0.18
Apr 18, 2012
Data from ASCEND-PD Phase III Study of IPX066 to be Presented at the American Academy of Neurology Conference
Apr 12, 2012
Impax Laboratories Confirms Patent Challenge Relating to Generic GRALISE® 300 mg and 600 mg
Apr 04, 2012
Impax Laboratories Schedules Conference Call and Webcast for First Quarter 2012 Financial Results
Mar 26, 2012
Impax Laboratories Enters Into Development, Supply and Distribution Agreement with TOLMAR, Inc.
Mar 14, 2012
Amneal Launches Escitalopram Oxalate Oral Solution
PDF format download (opens in new window)
Mar 01, 2012
Impax Laboratories to Present at the Cowen and Company Health Care Conference
Feb 28, 2012
Impax Laboratories Fourth Quarter 2011 EPS Increases 74% to $0.33
Feb 24, 2012
Impax Laboratories to Present at the RBC Capital Markets’ Healthcare Conference
Feb 23, 2012
FDA Accepts Impax Pharmaceuticals NDA Filing for IPX066 for the Treatment of Idiopathic Parkinson’s Disease
Feb 13, 2012
Amneal Pharmaceuticals CEO Kicks Off 2012 HIA-LI CEO Roundtable Series
PDF format download (opens in new window)
Feb 09, 2012
Impax Laboratories Provides Update on Status of Warning Letter Resolution for its Hayward Facility
Feb 01, 2012
Impax Pharmaceuticals Licenses Exclusive U.S. Commercialization Rights to Zomig® (zolmitriptan) from AstraZeneca
Jan 26, 2012
Impax Laboratories Schedules Conference Call and Webcast for Fourth Quarter and Full Year 2011 Financial Results
Jan 04, 2012
Impax Laboratories to Present at the J.P. Morgan Healthcare Conference

Investor Faq

Get answers to important investor relation questions.

More

Investor Tools

  • Email Alerts
  • RSS Feeds
  • Email Page

IR Contact

Get answers to your investor relation questions.

More
  • Privacy Policy
  • Copyright & Legal Disclaimer
  • Web Accessibility
© Amneal Pharmaceuticals LLC.
All rights reserved.
Powered By Q4 Inc. 5.86.0.1 (opens in new window)
Back to top